<DOC>
	<DOCNO>NCT01956201</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Atorvastatin Fenofibrate compare atorvastatin monotherapy mixed hypercholesterolemic patient .</brief_summary>
	<brief_title>Efficacy Safety Fenofibrate Added Atorvastatin Compared With Atorvastatin</brief_title>
	<detailed_description>Multi center , randomize , double-blind , parallel-group , therapeutic confirmatory study Primary Outcome Measure : The mean percent change Non-HDL Cholesterol [ Time Frame : baseline week 8 ] Secondary Outcome Measures : The achievement rate LDL-C &lt; 100mg/dl , Non-HDL-C &lt; 130mg/dl [ Time Frame : baseline week 8 ] The mean percent change LDL-C , HDL-C , TG , TC , Apo-AI , Apo-B [ Time Frame : baseline week 4 , 8 ] The mean percent change Non-LDL-C/HDL-C , TC/HDL-C , LDL-C/HDL-C , Apo-B/Apo-AI [ Time Frame : baseline week 4 , 8 ] The mean percent change Fibrinogen , hs-CRP [ Time Frame : baseline week 4 , 8 ] Safety evaluation [ Time Frame : Treatment period Extension period ]</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>&gt; 19 year old High risk patient Coronary Heart Disease ( apply 1 CHD risk factor list ) 1 . Patient Coronary Heart Disease 2 . Patient carotid artery disease , peripheral blood vessel disease , abdominal aneurysm 3 . Patient diabetes ( HbA1C≤9.0 % ) 4 . 10year risk CHD &gt; 20 % ( Framingham 10year risk score calculation ) At Visit 1 ( Screening ) 1 . 100mg/dl≥LDLC , 150mg/dl≤TG≤500mg/dl 4weeks Atorvastatin 20mg monotherapy runin period 2 . LDLC &lt; 100mg/dl , 150mg/dl≤TG≤500mg/dl If treat Atorvastatin 20mg monotherapy 4weeks prior study At Visit 2 ( After 4weeks Atorvastatin monotherapy runin period ) LDL &lt; 100mg/dl , 150mg/dl≤TG≤500mg/dl Patients acute artery disease within 3 month Patients congestive heart failure ( NYHA class III~IV ) uncontrolled arrhythmia within 6 month Patients uncontrolled hypertension ( SBP &gt; 160mmHg DBP &gt; 95mmHg ) TSH &gt; 1.5X ULN Patients myopathy , rhabdomyolysis CK &gt; 2X ULN Hypersensitive Atorvastatin and/or Fenofibrate photoallergy phototoxicity fibrate and/or ketoprofen treatment Serum Creatinine &gt; 2.5mg/dl , AST ALT &gt; 2X ULN History drug alcohol abuse within 6 month History GI tract surgery disability drug absorption Women pregnant , breastfeed Patients gallbladder disease Patients biliary cirrhosis Patients pancreatitis ( acute pancreatitis exclude due severe hypertriglyceridemia ) Patients treat investigational drug within 4 week time consent obtain History malignant tumor include leukemia , lymphoma within 5 year Patients must treat medication prohibit concomitant use study period Not eligible participate study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>